TABLE 1.
Patient Characteristics Before Injection with 99mTc-ADAPT6
| Patient no | Age (y) | HER2 status of primary tumor | Primary tumor ER/PgR | Stage |
| 500 μg; mean tumor size,23 ± 8 mm | ||||
| 1 | 36 | 3+ (IHC) | ER+/PgR− | IIB (T2N1M0) |
| 2 | 63 | 3+ (IHC) | ER−/PgR− | IIIA (T3N1M0) |
| 3 | 50 | 3+ (IHC) | ER+/PgR− | IIIA (T2N2M0) |
| 4 | 61 | 3+ (IHC) | ER−/PgR− | IIB (T2N1M0) |
| 5 | 64 | 2+ (IHC)/FISH+ | ER-/PgR− | IIIB (T2N1M0)/IV (T2N3M1)* |
| 6 | 34 | 0 (IHC) | ER+/PgR+ | I (T1N0M0) |
| 7 | 47 | 0 (IHC) | ER+;/PgR+ | IIA (T2N0M0) |
| 8 | 41 | 0 (IHC) | ER+/PgR+ | IIA (T2N0M0) |
| 9 | 63 | 1+ (IHC) | ER+/PgR+ | IIB (T2N1M0) |
| 10 | 59 | 1+ (IHC) | ER+/PgR− | IIA (T2N0M0) |
| 11 | 40 | 0 (IHC) | ER−/PgR− | IIIA (T3N1M0) |
| 1,000 μg; mean tumor size,31 ± 11 mm | ||||
| 12 | 34 | 3+ (IHC) | ER+/PgR− | IIA (T2N0M0) |
| 13 | 37 | 3+ (IHC) | ER+/PgR− | IIA (T1N1M0) |
| 14 | 43 | 2+ (IHC)/FISH+ | ER+/PgR+ | IIA (T2N0M0) |
| 15 | 36 | 3+ (IHC) | ER+/PgR+ | IIA (T1N1M0) |
| 16 | 33 | 3+ (IHC) | ER−/PgR− | IIA (T2N0M0) |
| 17 | 58 | 3+ (IHC)/2+ (IHC)/FISH−† | ER+/PgR+ | I (T1N0M0) |
| 18 | 51 | 1+ (IHC) | ER+/PgR− | IIA (T2N0M0) |
| 19 | 63 | 1+ (IHC) | ER+/PgR+ | IIA (T2N0M0) |
| 20 | 62 | 0 (IHC) | ER−/PgR− | IIA (T2N0M0) |
| 21 | 71 | 1+ (IHC) | ER+/PgR− | IIA (T2N0M0) |
| 22 | 42 | 0 (IHC) | ER+/PgR+ | IIA (T2N0M0) |
| 250 μg; mean tumor size,30 ± 10 mm | ||||
| 23 | 51 | 2+ (IHC)/FISH+ | ER+/PgR− | IIA (T2N0M0) |
| 24 | 48 | 2+ (IHC)/FISH+ | ER+/PgR− | IIA (T2N0M0) |
| 25 | 61 | 2+ (IHC)/FISH+ | ER+/PgR+ | IIA (T4N1M0) |
| 26 | 39 | 3+ (IHC) | ER+/PgR− | IIA (T2N0M0) |
| 27 | 29 | 2+ (IHC)/FISH- | ER+/PgR+ | IIA (T2N0M0) |
| 28 | 62 | 1+ (IHC) | ER+/PgR+ | I (T1N0M0) |
| 29 | 48 | 1+ (IHC) | ER−; PgR− | I (T1N0M0) |
*
Staging was changed as imaging revealed distant metastases.
†
FISH analysis after imaging confirmed HER2-negative status.
ER = estrogen receptor; IHC = immunohistochemistry; PgR = progesterone receptor.